Sage Therapeutics, Inc. (SG7.F)
| Previous close | 11.15 |
| Open | 11.06 |
| Bid | 11.02 x N/A |
| Ask | 11.08 x N/A |
| Day's range | 10.91 - 11.06 |
| 52-week range | 10.15 - 55.00 |
| Volume | |
| Avg. volume | 47 |
| Market cap | 656.887M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sage Therapeutics to Participate in Upcoming May Investor Conferences
CAMBRIDGE, Mass., May 07, 2024--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May:
- Business Wire
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass., April 25, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.
- Business Wire
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
CAMBRIDGE, Mass., April 17, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD). The PRECEDENT Study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on th
